41,500 Shares in Globus Medical, Inc. $GMED Purchased by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 41,500 shares of the medical device company’s stock, valued at approximately $3,623,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. increased its position in Globus Medical by 389.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,889 shares of the medical device company’s stock worth $427,000 after purchasing an additional 3,890 shares in the last quarter. Employees Retirement System of Texas purchased a new stake in Globus Medical during the 4th quarter worth about $1,035,000. Steel Grove Capital Advisors LLC purchased a new stake in Globus Medical during the 4th quarter worth about $274,000. Flputnam Investment Management Co. purchased a new stake in Globus Medical during the 4th quarter worth about $260,000. Finally, Summitry LLC increased its position in Globus Medical by 18.6% during the 4th quarter. Summitry LLC now owns 7,994 shares of the medical device company’s stock worth $698,000 after purchasing an additional 1,255 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

NYSE GMED opened at $82.00 on Monday. The firm has a market capitalization of $11.13 billion, a P/E ratio of 19.07, a P/E/G ratio of 1.69 and a beta of 0.95. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The business’s 50-day simple moving average is $87.01 and its 200-day simple moving average is $88.43.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GMED has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Royal Bank Of Canada lifted their price objective on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Truist Financial set a $115.00 price target on Globus Medical in a report on Wednesday, February 25th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Barclays lifted their price target on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.